However, the difference in YKL-40 between patients and controls in the study cited above was relatively small, with a large overlap between groups, and an independent smaller study could not reproduce the group difference [12], suggesting that alterations of CSF YKL-40 in AD are too small for this biomarker to be of diagnostic usability. The gene discussed is CHI3L1; the disease is Alzheimer disease.